Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-89862175 for Advanced Solid Tumors
NCT07223125Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of JNJ-89862175 in solid tumor, sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 21 days and Adverse Events. Started Oct 2025; status: recruiting.
02
Drugs
JNJ-89862175
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07223125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223125.